PDI Therapeutics will focus on the development of novel stand-alone or combination immunotherapies to enlist the body’s immune system for fighting cancer. The company is named for protein
Plumiaz failed to demonstrate its bioequivalence to Diastat rectal gel, which was required to support a refiling of the nasal spray’s new drug application earlier planned for the
The studies have been designed to give an array of additional data on reduction in symptoms, efficacy, quality of life benefits, to improve understanding about heart failure and
The engagement will leverage the capabilities of Inovalon’s data platforms and Avalere’s extensive industry experience, to support Bristol-Myers Squibb’s real-world outcomes and value-based contracting initiatives. The application of
EVK-001 is the Company’s novel nasal spray for delivery of metoclopramide for the symptomatic relief of acute and recurrent diabetic gastroparesis in women. Pursuant to the agreement, COSMA
VYXEOS is an investigational product in development as a treatment for AML and other blood cancers.’ The Breakthrough Therapy designation is primarily based upon the positive results from
Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with metastatic colorectal cancer. The initiation of this study
Through a 68-30 vote, the house has supported the release of emergency funding to restrict the Zika virus. Recently, AIDS Healthcare Foundation (AHF) urged the US Congress to
NICE said in draft guidance that the breast cancer drug pertuzumab could not be recommended to treat HER2-positive breast cancer due to uncertainties over its long-term health benefits.
The approval pertains to patients who have locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-based chemotherapy, or within 12 months of receiving either neoadjuvant
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.